KALA
Kala Pharmaceuticals Inc
NASDAQ: KALA · HEALTHCARE · BIOTECHNOLOGY
$0.11
-3.93% today
Updated 2026-04-30
Market cap
$110.98M
P/E ratio
—
P/S ratio
23.75x
EPS (TTM)
$-3.31
Dividend yield
—
52W range
$0 – $21
Volume
9.1M
Kala Pharmaceuticals Inc (KALA) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.07M | $11.72M | $8.45M | $46.33M | $116.13M | $220.97M | $154.32M | $221.61M | $139.43M | $86.82M | $55.95M | $55.48M |
| Cash & equivalents | $5.34M | $10.62M | $5.76M | $45.47M | $114.56M | $170.90M | $85.45M | $77.26M | $92.14M | $70.50M | $50.90M | $51.18M |
| Current assets | $5.97M | $10.78M | $5.87M | $45.63M | $115.21M | $177.03M | $105.48M | $171.38M | $124.37M | $85.94M | $52.87M | $52.80M |
| Total liabilities | $6.87M | $8.46M | $14.24M | $134.09M | $26.45M | $115.98M | $124.63M | $121.61M | $122.62M | $67.85M | $48.45M | $43.15M |
| Current liabilities | $5.58M | $2.95M | $5.51M | $5.55M | $14.46M | $17.01M | $24.77M | $22.23M | $37.42M | $25.68M | $8.35M | $16.96M |
| Long-term debt | — | $4.66M | $7.79M | $9.10M | $11.99M | $70.23M | $71.18M | $72.24M | $78.93M | $37.94M | $34.19M | $20.10M |
| Shareholder equity | $202000.00 | $3.26M | $-5.79M | $-87.76M | $89.68M | $104.99M | $29.69M | $100.00M | $16.80M | $18.97M | $7.50M | $12.33M |
| Retained earnings | $-22.93M | $-42.29M | $-58.97M | $-92.14M | $-134.37M | $-201.11M | $-295.46M | $-399.78M | $-542.39M | $-587.21M | $-629.41M | $-667.92M |
| Accounts receivable | $303000.00 | $38000.00 | — | — | — | $1.03M | $13.10M | $9.85M | $17.45M | $6.50M | $236000.00 | — |
| Inventory | — | — | — | — | $0.00 | $4.09M | $4.65M | $5.23M | $8.64M | $7.67M | — | — |
| Goodwill | — | — | — | — | $0.00 | — | — | — | — | — | — | — |